Nkarta (NKTX) Cash from Investing Activities (2019 - 2026)
Nkarta's quarterly Cash from Investing Activities came in at $15.9 million in Q1 2026, down 70.71% year-on-year from $54.3 million in Q1 2025, and up 1342.88% quarter-over-quarter from $1.1 million in Q4 2025.
Nkarta has reported Cash from Investing Activities for 8 years, with the latest figure at $15.9 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities fell 70.71% year-over-year to $15.9 million; the trailing twelve-month figure through Mar 2026 stood at $61.9 million (up 164.01% YoY), and the FY2025 full-year result was $100.3 million, up 177.43% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at $15.9 million, up from $1.1 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $54.3 million in Q1 2025, with the low at -$109.3 million in Q2 2022.
- Average Cash from Investing Activities over 5 years is -$7.0 million, with a median of $4.7 million recorded in 2022.
- Year-over-year, Cash from Investing Activities jumped 3699.32% in 2023 and plunged 3294.04% in 2024.
- Tracing NKTX's Cash from Investing Activities over 5 years: stood at $4.7 million in 2022, then jumped by 233.62% to $15.8 million in 2023, then sank by 128.54% to -$4.5 million in 2024, then jumped by 124.4% to $1.1 million in 2025, then soared by 1342.88% to $15.9 million in 2026.
- The last three Cash from Investing Activities figures came in at $15.9 million (Q1 2026), $1.1 million (Q4 2025), and $25.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.89 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 638.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -431.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -428.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - | 15.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.92 Mn |
| Mar 31, 2026 | 15.92 Mn |
| Dec 31, 2025 | 1.10 Mn |
| Dec 31, 2025 | 1.10 Mn |
| Sep 30, 2025 | 25.39 Mn |
| Sep 30, 2025 | 25.39 Mn |
| Jun 30, 2025 | 19.49 Mn |
| Jun 30, 2025 | 19.49 Mn |
| Mar 31, 2025 | 54.34 Mn |
| Mar 31, 2025 | 54.34 Mn |
| Dec 31, 2024 | -4.52 Mn |
| Dec 31, 2024 | -4.52 Mn |
| Sep 30, 2024 | -38.90 Mn |
| Sep 30, 2024 | -38.90 Mn |
| Jun 30, 2024 | -107.63 Mn |
| Jun 30, 2024 | -107.63 Mn |
| Mar 31, 2024 | 21.49 Mn |
| Mar 31, 2024 | 21.49 Mn |
| Dec 31, 2023 | 15.84 Mn |
| Dec 31, 2023 | 15.84 Mn |
| Sep 30, 2023 | 29.42 Mn |
| Sep 30, 2023 | 29.42 Mn |
| Jun 30, 2023 | -3.17 Mn |
| Jun 30, 2023 | -3.17 Mn |
| Mar 31, 2023 | 36.93 Mn |
| Mar 31, 2023 | 36.93 Mn |
| Dec 31, 2022 | 4.75 Mn |
| Dec 31, 2022 | 4.75 Mn |
| Sep 30, 2022 | -79.11 Mn |
| Sep 30, 2022 | -79.11 Mn |
| Jun 30, 2022 | -109.30 Mn |
| Jun 30, 2022 | -109.30 Mn |
| Mar 31, 2022 | -1.03 Mn |
| Mar 31, 2022 | -1.03 Mn |
| Dec 31, 2021 | -17.84 Mn |
| Dec 31, 2021 | -17.84 Mn |
| Sep 30, 2021 | 91.51 Mn |
| Sep 30, 2021 | 91.51 Mn |
| Jun 30, 2021 | -20.95 Mn |
| Jun 30, 2021 | -20.95 Mn |
| Mar 31, 2021 | -20.19 Mn |
| Mar 31, 2021 | -20.19 Mn |
| Dec 31, 2020 | -78.72 Mn |
| Dec 31, 2020 | -78.72 Mn |
| Sep 30, 2020 | -139.07 Mn |
| Sep 30, 2020 | -139.07 Mn |
| Jun 30, 2020 | 2.81 Mn |
| Jun 30, 2020 | 2.81 Mn |
| Mar 31, 2020 | 4.90 Mn |
| Mar 31, 2020 | 4.90 Mn |
| Dec 31, 2019 | -16.99 Mn |
| Dec 31, 2019 | -16.99 Mn |
| Sep 30, 2019 | -601,199.00 |
| Sep 30, 2019 | -601,199.00 |